Handelen Biodesix, Inc. - BDSX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.0556 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 1.7072 |
| Open* | 1.6873 |
| 1-Jaarlijkse Verandering* | -7.8% |
| Dagelijks bereik* | 1.6873 - 1.7372 |
| 52 wekelijks bereik | 0.96-3.00 |
| Weekgemiddelde volume (10 dagen) | 142.92K |
| Gemiddeld volume (3 maanden) | 2.52M |
| Marktkapitalisatie | 134.90M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 77.97M |
| Omzet | 38.21M |
| EPS | -1.60 |
| Dividend (opbrengst %) | N/A |
| Beta | -100.00K |
| Volgende inkomsten datum | May 9, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2023 | 1.7172 | 0.0100 | 0.59% | 1.7072 | 1.7372 | 1.6473 |
| Mar 27, 2023 | 1.7072 | -0.0200 | -1.16% | 1.7272 | 1.7272 | 1.6773 |
| Mar 24, 2023 | 1.7073 | 0.0800 | 4.92% | 1.6273 | 1.7073 | 1.6273 |
| Mar 23, 2023 | 1.6174 | -0.2596 | -13.83% | 1.8770 | 1.8770 | 1.6074 |
| Mar 22, 2023 | 1.8570 | 0.0799 | 4.50% | 1.7771 | 1.8969 | 1.7472 |
| Mar 21, 2023 | 1.7771 | 0.0300 | 1.72% | 1.7471 | 1.7871 | 1.7372 |
| Mar 20, 2023 | 1.7172 | -0.0399 | -2.27% | 1.7571 | 1.7771 | 1.6173 |
| Mar 17, 2023 | 1.7571 | -0.0300 | -1.68% | 1.7871 | 1.8670 | 1.7472 |
| Mar 16, 2023 | 1.7871 | -0.0799 | -4.28% | 1.8670 | 1.9070 | 1.7172 |
| Mar 15, 2023 | 1.8770 | 0.2896 | 18.24% | 1.5874 | 1.8870 | 1.5874 |
| Mar 14, 2023 | 1.6373 | -0.0100 | -0.61% | 1.6473 | 1.6973 | 1.6274 |
| Mar 13, 2023 | 1.6473 | 0.1498 | 10.00% | 1.4975 | 1.7172 | 1.4975 |
| Mar 10, 2023 | 1.5675 | 0.1398 | 9.79% | 1.4277 | 1.6573 | 1.3877 |
| Mar 9, 2023 | 1.4776 | -0.2096 | -12.42% | 1.6872 | 1.6873 | 1.4676 |
| Mar 8, 2023 | 1.6673 | -0.0898 | -5.11% | 1.7571 | 1.7971 | 1.6673 |
| Mar 7, 2023 | 1.7771 | 0.0599 | 3.49% | 1.7172 | 1.7971 | 1.7172 |
| Mar 6, 2023 | 1.7572 | -0.3194 | -15.38% | 2.0766 | 2.1366 | 1.7172 |
| Mar 3, 2023 | 1.9668 | 0.0000 | 0.00% | 1.9668 | 2.0467 | 1.9668 |
| Mar 2, 2023 | 1.9668 | -0.0300 | -1.50% | 1.9968 | 2.0368 | 1.9569 |
| Mar 1, 2023 | 1.9868 | -0.0399 | -1.97% | 2.0267 | 2.0467 | 1.9369 |
Biodesix, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 38.212 | 54.506 | 45.557 | 24.552 | 20.432 |
| Inkomsten | 38.212 | 54.506 | 45.557 | 24.552 | 20.432 |
| Kosten van opbrengsten, totaal | 14.154 | 30.518 | 21.998 | 6.074 | 4.406 |
| Brutowinst | 24.058 | 23.988 | 23.559 | 18.478 | 16.026 |
| Totale bedrijfskosten | 95.78 | 93.148 | 68.491 | 51.293 | 44.095 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 58.458 | 47.958 | 32.328 | 30.637 | 25.899 |
| Onderzoek & Ontwikkeling | 13.102 | 12.789 | 10.818 | 10.468 | 8.188 |
| Ongebruikelijke uitgaven (inkomsten) | 7.062 | -2.298 | 3.451 | 1.739 | |
| Other Operating Expenses, Total | 0 | 1.622 | 0.818 | 0.663 | 3.863 |
| Bedrijfsresultaat | -57.568 | -38.642 | -22.934 | -26.741 | -23.663 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -8.072 | -4.508 | -7.586 | -2.953 | -2.892 |
| Overige, Netto | 0.193 | -0.009 | -0.83 | -1.032 | 0.389 |
| Netto inkomen voor belastingen | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Netto inkomen na belastingen | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Netto inkomen voor extra. Posten | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Netto inkomen | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Verwaterd Netto Inkomen | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Verwaterd Gewogen Gemiddelde Aandelen | 42.103 | 27.365 | 26.5615 | 26.2541 | 26.2541 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -1.55445 | -1.57716 | -1.18028 | -1.17033 | -0.99665 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Verwaterde Genormaliseerde Winst per Aandeel | -1.38672 | -1.66114 | -1.14948 | -1.03889 | -0.93041 |
| Depreciation / Amortization | 3.004 | 2.559 | 2.529 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Totale inkomsten | 9.607 | 11.107 | 10.95 | 6.548 | 7.224 |
| Inkomsten | 9.607 | 11.107 | 10.95 | 6.548 | 7.224 |
| Kosten van opbrengsten, totaal | 3.306 | 3.633 | 3.98 | 3.235 | 2.493 |
| Brutowinst | 6.301 | 7.474 | 6.97 | 3.313 | 4.731 |
| Totale bedrijfskosten | 27.474 | 21.769 | 25.528 | 21.009 | 19 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 16.626 | 15.114 | 15.235 | 14.487 | 13.558 |
| Onderzoek & Ontwikkeling | 3.565 | 2.97 | 3.361 | 3.206 | 2.852 |
| Ongebruikelijke uitgaven (inkomsten) | 3.977 | 0.052 | 2.952 | 0.081 | 0.097 |
| Bedrijfsresultaat | -17.867 | -10.662 | -14.578 | -14.461 | -11.776 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -2.55 | -3.039 | -1.346 | -1.137 | -1.496 |
| Overige, Netto | 0.079 | 0.002 | 0.1 | 0.012 | -0.01 |
| Netto inkomen voor belastingen | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Netto inkomen na belastingen | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Netto inkomen voor extra. Posten | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Netto inkomen | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Verwaterd Netto Inkomen | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Verwaterd Gewogen Gemiddelde Aandelen | 57.553 | 40.448 | 39.239 | 31.07 | 27.059 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.35338 | -0.33868 | -0.40327 | -0.50164 | -0.49085 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Verwaterde Genormaliseerde Winst per Aandeel | -0.28428 | -0.3374 | -0.32804 | -0.49903 | -0.48727 |
| Other Operating Expenses, Total | 0 | 0 | 0 | 0 | 0 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Totaal vlottende activa | 43.613 | 86.14 | 12.7 | 9.913 |
| Geldmiddelen en kortetermijnbeleggingen | 32.712 | 62.126 | 5.286 | 5.914 |
| Geldmiddelen & Equivalenten | 32.712 | 62.126 | 5.286 | 5.914 |
| Totale Vorderingen, Netto | 3.656 | 15.304 | 5.292 | 1.892 |
| Accounts Receivable - Trade, Net | 3.656 | 15.304 | 5.292 | 1.892 |
| Other Current Assets, Total | 7.245 | 8.71 | 2.122 | 2.107 |
| Total Assets | 76.097 | 121.07 | 41.633 | 39.057 |
| Property/Plant/Equipment, Total - Net | 4.179 | 3.178 | 2.12 | 1.388 |
| Property/Plant/Equipment, Total - Gross | 10.928 | 9.902 | 8.506 | 6.956 |
| Accumulated Depreciation, Total | -6.749 | -6.724 | -6.386 | -5.568 |
| Goodwill, Net | 15.031 | 15.031 | 11.631 | 10.804 |
| Intangibles, Net | 11.617 | 13.26 | 15.092 | 16.852 |
| Other Long Term Assets, Total | 1.657 | 3.461 | 0.09 | 0.1 |
| Total Current Liabilities | 28.96 | 32.125 | 22.6 | 4.468 |
| Accounts Payable | 1.662 | 8.964 | 1.717 | 0.886 |
| Accrued Expenses | 4.899 | 4.69 | 1.899 | 1.568 |
| Notes Payable/Short Term Debt | 0 | 0 | 12.045 | 0 |
| Other Current Liabilities, Total | 22.38 | 6.631 | 6.939 | 2.014 |
| Total Liabilities | 56.37 | 79.904 | 76.213 | 53.125 |
| Total Long Term Debt | 9.993 | 15.926 | 23.812 | 23.099 |
| Long Term Debt | 9.993 | 15.926 | 23.812 | 23.099 |
| Other Liabilities, Total | 17.417 | 31.853 | 29.801 | 25.558 |
| Total Equity | 19.727 | 41.166 | -34.58 | -14.068 |
| Redeemable Preferred Stock | 0 | 0 | 193.959 | 183.962 |
| Common Stock | 0.031 | 0.027 | 0.001 | 0.001 |
| Additional Paid-In Capital | 321.669 | 299.953 | 2.324 | 2.107 |
| Retained Earnings (Accumulated Deficit) | -301.973 | -258.814 | -230.864 | -200.138 |
| Total Liabilities & Shareholders’ Equity | 76.097 | 121.07 | 41.633 | 39.057 |
| Total Common Shares Outstanding | 30.7896 | 26.5615 | 26.2541 | 26.2541 |
| Current Port. of LT Debt/Capital Leases | 0.019 | 11.84 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 27.233 | 43.613 | 56.445 | 68.45 | 81.244 |
| Geldmiddelen en kortetermijnbeleggingen | 16.427 | 32.712 | 47.913 | 56.349 | 55.329 |
| Geldmiddelen & Equivalenten | 16.427 | 32.712 | 47.913 | 56.349 | 55.329 |
| Totale Vorderingen, Netto | 3.774 | 3.656 | 2.784 | 5.281 | 18.367 |
| Accounts Receivable - Trade, Net | 3.774 | 3.656 | 2.784 | 5.281 | 18.367 |
| Other Current Assets, Total | 7.032 | 7.245 | 5.748 | 6.82 | 7.548 |
| Total Assets | 61.651 | 76.097 | 89.997 | 101.804 | 115.486 |
| Property/Plant/Equipment, Total - Net | 6.247 | 4.179 | 4.432 | 3.378 | 3.387 |
| Property/Plant/Equipment, Total - Gross | 13.409 | 10.928 | 11.827 | 10.471 | 10.369 |
| Accumulated Depreciation, Total | -7.162 | -6.749 | -7.395 | -7.093 | -6.982 |
| Goodwill, Net | 15.031 | 15.031 | 15.031 | 15.031 | 15.031 |
| Intangibles, Net | 11.131 | 11.617 | 11.992 | 12.4 | 12.821 |
| Other Long Term Assets, Total | 2.009 | 1.657 | 2.097 | 2.545 | 3.003 |
| Total Current Liabilities | 29.811 | 28.96 | 22.787 | 21.272 | 16.124 |
| Accounts Payable | 2.12 | 1.662 | 1.6 | 1.16 | 3.747 |
| Accrued Expenses | 4.597 | 4.899 | 3.533 | 2.959 | 2.622 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.051 | 0.019 | 0.02 | 3.106 | 2.707 |
| Other Current Liabilities, Total | 23.043 | 22.38 | 17.634 | 14.047 | 7.048 |
| Total Liabilities | 53.87 | 56.37 | 73.964 | 76.031 | 79.054 |
| Total Long Term Debt | 10.055 | 9.993 | 29.975 | 29.955 | 30.328 |
| Long Term Debt | 10.055 | 9.993 | 29.975 | 29.955 | 30.328 |
| Other Liabilities, Total | 14.004 | 17.417 | 21.202 | 24.804 | 32.602 |
| Total Equity | 7.781 | 19.727 | 16.033 | 25.773 | 36.432 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.032 | 0.031 | 0.027 | 0.027 | 0.027 |
| Additional Paid-In Capital | 325.308 | 321.669 | 304.697 | 302.923 | 302.18 |
| Retained Earnings (Accumulated Deficit) | -317.559 | -301.973 | -288.691 | -277.177 | -265.775 |
| Total Liabilities & Shareholders’ Equity | 61.651 | 76.097 | 89.997 | 101.804 | 115.486 |
| Total Common Shares Outstanding | 31.8893 | 30.7896 | 27.0201 | 26.9489 | 26.7854 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -43.159 | -31.35 | -30.726 | -26.166 |
| Geldmiddelen uit Operationele Activiteiten | -28.223 | -21.366 | -21.726 | -17.677 |
| Geldmiddelen uit Operationele Activiteiten | 3.178 | 2.903 | 2.793 | 1.74 |
| Niet-Geldelijke Posten | 7.167 | 11.882 | 7.852 | 6.496 |
| Veranderingen in het Operationeel Kapitaal | 4.591 | -4.801 | -1.645 | 0.253 |
| Geldmiddelen uit Investeringsactiviteiten | -2.547 | -2.927 | -1.872 | -0.617 |
| Kapitaaluitgaven | -2.547 | -2.177 | -1.416 | -0.617 |
| Overige Cash Flow investeringsposten, Totaal | 0 | -0.75 | -0.456 | 0 |
| Geldmiddelen uit Financieringsactiviteiten | 1.262 | 81.131 | 22.972 | 19.032 |
| Financiering van Cash Flow Posten | -0.5 | -8.249 | -0.119 | -0.283 |
| Uitgifte (Aflossing) van aandelen, netto | 17.112 | 73.34 | 10.047 | 8.55 |
| Uitgifte (Aflossing) van Schulden, Netto | -15.35 | 16.04 | 13.044 | 10.765 |
| Nettowijziging in Geldmiddelen | -29.508 | 56.838 | -0.626 | 0.738 |
| Contant Betaalde Rente | 1.676 | 1.844 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -15.586 | -43.159 | -29.877 | -18.363 | -6.961 |
| Cash From Operating Activities | -13.099 | -28.223 | -18.026 | -10.236 | -11.326 |
| Cash From Operating Activities | 0.908 | 3.178 | 2.323 | 1.523 | 0.746 |
| Non-Cash Items | 2.674 | 7.167 | 4.704 | 5.336 | 3.721 |
| Changes in Working Capital | -1.095 | 4.591 | 4.824 | 1.268 | -8.832 |
| Cash From Investing Activities | -0.352 | -2.547 | -1.906 | -0.864 | -0.516 |
| Capital Expenditures | -0.352 | -2.547 | -1.906 | -0.864 | -0.516 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | -2.834 | 1.262 | 5.625 | 5.229 | 4.951 |
| Financing Cash Flow Items | -4.6 | -0.5 | 0.232 | -0.109 | -0.108 |
| Issuance (Retirement) of Stock, Net | 1.674 | 17.112 | 0.739 | 0.679 | 0.475 |
| Issuance (Retirement) of Debt, Net | 0.092 | -15.35 | 4.654 | 4.659 | 4.584 |
| Net Change in Cash | -16.285 | -29.508 | -14.307 | -5.871 | -6.891 |
| Cash Interest Paid | 0.223 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Schuler (Jack W) | Individual Investor | 25.5879 | 19952112 | 8695652 | 2022-11-21 | |
| Kennedy (Lawrence T Jr.) | Individual Investor | 19.0156 | 14827404 | 0 | 2023-01-03 | MED |
| Patience (John) | Individual Investor | 9.0025 | 7019695 | 1739130 | 2022-11-21 | LOW |
| Birchview Capital, LP | Investment Advisor | 6.4632 | 5039633 | 2884624 | 2022-12-31 | LOW |
| AIGH Capital Management, LLC. | Private Equity | 5.8936 | 4595512 | -973389 | 2022-12-31 | MED |
| Cawthorn (Robert E) | Individual Investor | 4.6838 | 3652220 | 1723341 | 2022-11-21 | LOW |
| Strobeck (Matthew W) | Individual Investor | 3.7251 | 2904668 | 1304345 | 2022-11-21 | LOW |
| Industrial Development Funding LLC | Corporation | 2.432 | 1896374 | 0 | 2022-03-01 | LOW |
| Worth Venture Partners, LLC | Investment Advisor/Hedge Fund | 1.9211 | 1497963 | 1497963 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.4189 | 1106403 | 866747 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.9923 | 773725 | 5000 | 2022-12-31 | LOW |
| Essex Investment Management Company, LLC | Investment Advisor/Hedge Fund | 0.4848 | 377994 | -29 | 2022-12-31 | LOW |
| Life Sciences Alternative Financing, L.L.C. | Corporation | 0.3771 | 294053 | 0 | 2022-03-01 | LOW |
| Cannell & Co. | Investment Advisor | 0.2637 | 205605 | 0 | 2022-12-31 | LOW |
| Hutton Scott | Individual Investor | 0.2561 | 199726 | 28499 | 2023-02-09 | HIGH |
| Massarany (Hany) | Individual Investor | 0.1769 | 137934 | 130434 | 2022-11-21 | HIGH |
| Hightower Advisors, LLC | Investment Advisor | 0.175 | 136434 | 136434 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1617 | 126122 | 2052 | 2022-12-31 | LOW |
| Endurant Capital Management LP | Hedge Fund | 0.1596 | 124430 | -5706 | 2022-12-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.1382 | 107788 | -10260 | 2022-12-31 | HIGH |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Biodesix, Inc. Company profile
Over Biodesix, Inc.
Biodesix, Inc. is een in de Verenigde Staten gevestigd bedrijf dat zich bezighoudt met de ontwikkeling en commercialisering van op bloed gebaseerde diagnostische tests voor oncologie. Het product van de onderneming Biodesix Lung Reflex integreert genomische en proteomische bloedgebaseerde resultaten om beide kanten van longkanker aan het licht te brengen. Zijn GeneStrat-test biedt bloedgebaseerde mutatieresultaten binnen 72 uur voor patiënten met niet-kleincellige longkanker (NSCLC). De VeriStrat-test biedt op bloed gebaseerde voorspellende en prognostische proteomische informatie voor NSCLC-patiënten die negatief reageren op EGFR-mutaties (EGFR wild-type) of van wie de EGFR-mutatiestatus onbekend is.
| Industry: | Medical & Diagnostic Laboratories |
Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen